Skip to content

The effectiveness of Levetiracetam and Sodium Valproate in Migraine headache prevention

Comparison effectiveness of Levetiracetam and Sodium Valproate in prevention of Migraine without aura

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171011036717N1
Enrollment
100
Registered
2017-12-03
Start date
2017-11-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine without aura

Interventions

Intervention 1: Sodium valproate, 500mg oral tablet, once a day for three months. Intervention 2: Levetiracetam, 250mg oral tablet? twice a day for three months.
Treatment - Drugs
Sodium valproate, 500mg oral tablet, once a day for three months.
Levetiracetam, 250mg oral tablet? twice a day for three months

Sponsors

Vice chancellor for Research, Ardabil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:The age of 16 to 65 years old who will be candidate to achieve prophylaxis of migraine by being diagnosed with migraine headaches. pregnancy and lactation liver failure kidney failure sedative medication non-migraine headaches

Exclusion criteria

Exclusion criteria: Exlusion criteria: pregnancy and lactation; liver and kidney failure; sedative medication; being smoker; non-migraine headaches.

Design outcomes

Primary

MeasureTime frame
Migraine Disability Assessment. Timepoint: Every month for three months. Method of measurement: Migraine Disability Assessment Test.

Secondary

MeasureTime frame
Intensity of migraine attacks. Timepoint: Every month for three months. Method of measurement: Asking from patient.;The number of migraine attacks. Timepoint: Every month for three months. Method of measurement: Asking from patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParham Sedigh Nia

Ardabil University of Medical Sciences

p.sedighnia@armus.ac.ir+98 45 3371 5498

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026